UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 37.00% | 3.76% | -20.98% | -42.70% | -36.43% |
| Total Depreciation and Amortization | 58.44% | 92.64% | 103.29% | 56.29% | 14.59% |
| Total Amortization of Deferred Charges | -204.88% | -- | -- | -- | 200.00% |
| Total Other Non-Cash Items | 12.36% | -6.20% | -22.17% | 6.43% | -5.59% |
| Change in Net Operating Assets | -1,107.86% | -1,028.69% | -693.11% | 210.35% | 71.33% |
| Cash from Operations | -29.06% | -54.81% | -67.87% | -43.26% | -43.55% |
| Capital Expenditure | 44.95% | 11.80% | 2.03% | -63.98% | -65.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 193.13% | 212.35% | 404.40% | 202.71% | -392.24% |
| Cash from Investing | 191.79% | 211.21% | 398.64% | 202.04% | -399.77% |
| Total Debt Issued | 166.85% | 166.85% | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 173.99% | -56.73% | -72.43% | -94.28% | -92.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -200.00% | -100.00% | -100.00% | -99.98% | -100.00% |
| Cash from Financing | 163.18% | -24.93% | -79.49% | -95.54% | -85.24% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.33% | 122.78% | -178.93% | -689.79% | -163.45% |